Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 3 3Phase 1/2 3

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 97Neoplasms 28Carcinoma, Non-Small-Cell Lung 27Neoplasm Metastasis 23Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Sarcoma 15Lung Neoplasms 14Biliary Tract Neoplasms 13Ovarian Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Lymphoma 10Cholangiocarcinoma 10Recurrence 9Hodgkin Disease 8Carcinoma, Transitional Cell 8Adenocarcinoma 8Lymphoma, Non-Hodgkin 7Triple Negative Breast Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Lymphoma, Follicular 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Gastrointestinal Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4

Interventions

Gemcitabine 3ensituximab 1Lead 1Immunotherapy, Adoptive 1Cetuximab 1Bevacizumab 1Atu027 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Pancreatic Ductal × Gemcitabine × Clear all
NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
1,130 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT01808638 2016-03-11

Atu027-I-02

Silence Therapeutics GmbH

Phase 1/2 Completed
29 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

NCT02529579 2015-08-20

Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer

Changhai Hospital

Phase 1/2 Unknown
187 enrolled
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡